Table 3 Characteristics of the prescribed AIT preparations and administration regimens
France | Germany | Spain | USA | Russia | Overall study population | |
|---|---|---|---|---|---|---|
Proportion of patients unaware of the type of allergen being administered: | ||||||
total population | 46 % | 18 % | 29 % | 20 % | 24 % | 28 % |
“early abandoners” | 40 % | 8 % | 19 % | 23 % | 12 % | 20 % |
“non-starters” | 50 % | 27 % | 38 % | 16 % | 36 % | 34 % |
Type of AIT formulation prescribed in the overall population: | ||||||
SCIT | 38 % | 61 % | 33 % | 88 % | 82 % | 60 % |
SLIT drops | 31 % | 10 % | 21 % | 8 % | 4 % | 15 % |
SLIT tablets | 24 % | 27 % | 46 % | 4 % | 14 % | 23 % |
unspecified | 7 % | 2 % | 0 % | 0 % | 0 % | 2 % |
Proportion of patients prescribed with a continuous regimen | 38 % | 27 % | 38 % | 76 % | 28 % | 41 % |